Aurinia Pharmaceuticals Inc.
AUPH scores 70.9 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-0.2 points) applied. AUPH's rank of #135 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| AUPH | 70.9 | 25.4 | 34.0% | 29.3% | $1.9B |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $13.8B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | โ |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $77M | $73M | $70M | $62M |
| Gross Profit | $69M | $65M | $63M | $54M |
| Operating Income | $33M | $30M | $20M | $22M |
| Net Income | $211M | $32M | $22M | $23M |
| EPS (Diluted) | $1.53 | $0.23 | $0.15 | $0.16 |
| Gross Margin | 89.0% | 88.4% | 89.8% | 86.3% |
| Operating Margin | 43.1% | 40.5% | 28.7% | 35.0% |
| Net Margin | 273.4% | 42.9% | 30.7% | 37.4% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $9.72 | $33.97 | 111% | Wide |
| 2022 | $4.07 | $23.42 | 140.8% | Wide |
| 2023 | $5.31 | $12.43 | 80.3% | Wide |
| 2024 | $4.71 | $10.67 | 77.5% | Wide |
| 2025 | $6.55 | $16.54 | 86.5% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.